NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

TScan Therapeutics, Inc. (TCRX) Stock Analysis

TScan Therapeutics, Inc. (TCRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TCRX

$0.39

+$0.02 (+5.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TCRX with… →

TCRX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.37
Previous Close
$0.37
Day's Range
0.37–0.42
52-Week Range
0.35–2.57
Volume
1.67M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.07
Valuation
Market Cap
$26.54M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.95
Financials (FY)
Revenue (FY)
$10.33M+266.65%
Net Income (FY)
−$129.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.50M
1-Year Return
−79.26%
Dividend and dates
Avg Volume
764.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TCRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−60.80%
2025−67.11%
2024−47.86%
2023+276.13%
2022−65.56%
2021 (partial year)−57.14%

As of September 4, 2026.

TCRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.33M−$129.77M−1256.8%
2024$2.82M−$127.50M−4527.7%
2023$21.05M−$89.22M−423.9%
2022$13.54M−$66.22M−489.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.33M—−$135.81M−$129.77M−1256.8%
2024$2.82M—−$134.82M−$127.50M−4527.7%
2023$21.05M—−$93.46M−$89.22M−423.9%
2022$13.54M—−$66.64M−$66.22M−489.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TCRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTCRXBiotechnology medianvs median
P/S ratio3.7315.260.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

TScan Therapeutics, Inc. (TCRX) carries a market capitalisation of $26.54M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 138 employees.

The most recent close on file for TCRX is $0.39, dated September 4, 2026. That is +$0.02 (+5.66%) against the previous close. Over the past 52 weeks the price has ranged from $0.35 to $2.57. The latest close sits 11.68% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $10.33M. Against the prior fiscal year total of $2.82M, that is a change of +266.65%. The same year closed with a net loss of $129.77M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.95.

Across the 4 fiscal years on file, revenue moves from $13.54M in 2022 to $10.33M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.73 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −79.26%. Across 5 years the annualized return works out at −45.98%. The reported beta is 1.07. Annualized volatility over the trailing 5 years is 99.59%.

Growth & Income

The record shows no dividend for TCRX.

2026 is still running; the price is −60.80% year to date. Across the complete calendar years on file, 2023 returned +276.13% and 2025 returned −67.11%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

TScan Therapeutics, Inc. (TCRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TScan Therapeutics, Inc. TCRX $26.54M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. TScan Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Visit website →